ADC (Antibody Drug Conjugate) is one of the major compounds in immuno-oncology, and a promising molecule to treat cancer. Owing to its high potential in cancer therapy, INOVOTION has tested and approved the use of ADCs in their chick embryo model whose predictivity and reliability provides a rapid way to determine in vivo ADCs’ efficiency and toxicity.

World ADC London, with more than 320 attendees across 140 organizations, is a major antibody drug conjugate conference that keeps ADC actors informed about the latest scientific and clinical advances, providing an ideal setting for creating new industry connections. Take this opportunity to meet at the congress our team member Arnaud Peyronnier, Sales Director at INOVOTION and learn more about our platform and our model!

For more information, feel free to contact us at: contact@inovotion.com.